Recent Updates
Recently added Catalysts
VTRS Positive Sentiment Score: 60/100

Viatris to Report First Quarter 2023 Financial Results on May 8, 2023 Viatris Inc. (NASDAQ: VTRS) plans to report its first quarter 2023 financial results on Monday, May 8 before the open of the U.S. financial markets....

Key Takeaway: Viatris Inc. (NASDAQ: VTRS) is scheduled to release its financial results for the first quarter of 2023 on May 8 before U.S. markets open. The event will feature a live webcast led by CEO Scott Smith, President Rajiv Malik, and CFO Sanjeev Narula at 8:30 a.m. ET. Investors can access the webcast through multiple channels, ensuring broader participation and engagement. Viatris continues to emphasize its commitment to delivering access to healthcare solutions globally.

Market Sentiment Analysis

POSITIVE FACTORS

  • Viatris is set to report its Q1 2023 financial results, indicating business activity.
  • The company invites the public to participate in its webcast, promoting transparency.
  • Viatris has a diverse portfolio of over 1,400 approved medicines across various therapeutic areas.
  • The presence of an experienced executive team to discuss the results can instill confidence.

Full Press Release Details

PITTSBURGH , April 12, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS ) plans to report its first quarter 2023 financial results on Monday, May 8 before the open of the U.S. financial markets. Chief Executive Officer Scott Smith , President Rajiv Malik , and Chief Financial Officer Sanjeev Narula also will host a webcast at 8:30 a.m. ET on May 8 to discuss the results.
Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 800-579-2543 or 785-424-1789 for international callers (Conference ID: VTRSQ123). A replay of the webcast also will be available on the website.
About Viatris Viatris Inc. (NASDAQ: VTRS ) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines and a variety of over-the-counter consumer products. With approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh , Shanghai and Hyderabad, India . Learn more at viatris.com and investor.viatris.com , and connect with us on Twitter at @ViatrisInc , LinkedIn , Instagram and YouTube .
SOURCE Viatris Inc.

21 %

About Viatris Inc.

Ticker Symbol: VTRS
Exchange: NASDAQ
Mission: Empower people worldwide to live healthier at every stage of life
Patient Reach: ~1 billion patients annually
Global Centers: Pittsburgh, Shanghai, Hyderabad

Frequently Asked Questions

When will Viatris report its Q1 2023 financial results?

Viatris will report its Q1 2023 financial results on May 8, 2023.

Who will host the financial results webcast?

CEO Scott Smith, President Rajiv Malik, and CFO Sanjeev Narula will host it.

How can I listen to the webcast of Viatris' earnings call?

You can listen live at investor.viatris.com or call 800-579-2543.

What is Viatris Inc. known for?

Viatris is a global healthcare company providing access to medicines worldwide.

How many approved medicines does Viatris offer?

Viatris' portfolio includes over 1,400 approved medicines across various areas.

Last updated: Apr 12, 2023